Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy ...
ImmunityBio (IBRX) shares added ~12% in the premarket on Wednesday after the Saudi Food and Drug Authority approved its ...
Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. The stock rose 6.6% to $3.01 on Wednesday. Shares are ...
InvestorsHub on MSN
ImmunityBio shares jump after Saudi approval of ANKTIVA for lung cancer
Shares of ImmunityBio (NASDAQ:IBRX) climbed 6% on Wednesday morning after the company said Saudi Arabia’s Food and Drug ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Beam Therapeutics shares climbed after the company said it plans to file an application for its risto-cel treatment and had reached alignment with the Food and Drug Administration on potential ...
Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check ...
In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback